Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2000
- Registration Number
- NCT07015905
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT06975787
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06970405
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
- Conditions
- Melanoma
- Interventions
- Drug: Fianlimab+cemiplimab
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06848088
- Locations
- 🇺🇸
Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸South Texas Oncology And Hematology, San Antonio, Texas, United States
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06836609
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, Greater London, United Kingdom
REGN5381 in Adult Participants With Uncontrolled Hypertension
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 732
- Registration Number
- NCT06833190
- Locations
- 🇬🇧
Protas, Car Park of Asda Pilsworth Road, Bury, United Kingdom
🇬🇧Protas, Car Park of Asda Huyton Supercentre, Huyton, Liverpool, United Kingdom
🇬🇧Protas, Two New Bailey Square, Salford, Manchester, United Kingdom
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
- Conditions
- Long Term Safety Following GM T Cell Therapy
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06798298
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT06787612
- Locations
- 🇺🇸
Avera Cancer Institute Sioux Falls, Sioux Falls, South Dakota, United States
ALN-APOC3 in Adult Participants With Dyslipidemia
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 136
- Registration Number
- NCT06784349
- Locations
- 🇲🇩
Arensia Exploratory Medicine at the Republican Clinical Hospital, Chisinau, Moldova, Republic of
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 550000
- Registration Number
- NCT06769412